Pérez-Pérez Manuel, Agostino Alessandro, de Sola-Llamas Carmen García, Ruvolo Michael, Vilches-Arenas Angel, Relimpio-López M Isabel, Espejo-Arjona Francisco, Macías-García Laura, De Miguel-Rodríguez Manuel, García-Escudero Antonio, Idoate Miguel A, Ríos-Martín Juan J
Department of Anatomic Pathology, Virgen Macarena University Hospital, Seville, Spain.
Diagnostics and Genomics Division, Agilent Technologies Italia S.p.A. Cernusco sul Naviglio, Milan, Italy.
Clin Exp Ophthalmol. 2023 Nov;51(8):822-834. doi: 10.1111/ceo.14302. Epub 2023 Oct 6.
Uveal melanoma (UM) is the eye's most common primary malignancy and there are no effective therapies for disseminated disease. It is important to try to know the patient's prognosis. The aim of this study was to reflect genetic variants, studied using NGS, of a series of 69 cases of UM and its correlation with histopathology and clinical progression.
We performed targeted NGS using a 519-gene panel.
There were selected 28 different mutated genes, showing a total of 231 genetic variants that affected the function of the protein. The most common secondary mutations occurred in SF3B1 (in 26%), followed by BAP1 (in 23%), LRP1B (22%) and FGFR4 (20%). BAP1 mutation was associated with a greater likelihood of metastases and with greater presence of epithelioid cells. LRP1B was also associated with presence of epithelioid cells SF3B1 mutation was significantly associated with a spindle morphology. We found variants in the RAD51B, TOP2A, PTPRD, TSC2, DHX9, PDK1 and MTOR that have not been previously reported in consulted databases. The presence of a mutation in: CHEK2, DHX9 and PDK1 was associated with metastases.
BAP1 is the most solid biomarker of a poor prognosis in UM and mutations can be detected using NGS. SF3B1 is associated with the spindle cell subtype of UM, which gives it probably a favourable prognostic value. Our study suggests that mutations in DHX9 and PDK1 can have prognostic value. These potential biomarkers are related to the PI3K/AKT/mTOR pathway and makes them candidates for developing new directed therapies.
葡萄膜黑色素瘤(UM)是眼部最常见的原发性恶性肿瘤,对于播散性疾病尚无有效的治疗方法。了解患者的预后情况很重要。本研究的目的是反映通过二代测序(NGS)研究的69例UM病例的基因变异及其与组织病理学和临床进展的相关性。
我们使用包含519个基因的基因panel进行靶向NGS。
共筛选出28个不同的突变基因,显示出总共231个影响蛋白质功能的基因变异。最常见的二次突变发生在SF3B1(26%),其次是BAP1(23%)、LRP1B(22%)和FGFR4(20%)。BAP1突变与转移的可能性更大以及上皮样细胞的更多存在相关。LRP1B也与上皮样细胞的存在相关。SF3B1突变与纺锤体形态显著相关。我们在RAD51B、TOP2A、PTPRD、TSC2、DHX9、PDK1和MTOR中发现了在参考数据库中先前未报道的变异。CHEK2、DHX9和PDK1中存在突变与转移相关。
BAP1是UM预后不良最可靠的生物标志物,可通过NGS检测到突变。SF3B1与UM的纺锤体细胞亚型相关,这可能赋予其良好的预后价值。我们的研究表明,DHX9和PDK1中的突变可能具有预后价值。这些潜在的生物标志物与PI3K/AKT/mTOR通路相关,使其成为开发新的靶向治疗药物的候选者。